Background and objective: Unrecognized obstructive sleep apnoea syndrome (OSAS) may lead to poor asthma control despite optimal therapy. We assessed asthma control, airway responsiveness, daytime sleepiness and health status at baseline and 3 months after continuous positive airway pressure (CPAP) treatment among asthma patients with nocturnal symptoms and OSAS. Methods: Patients with nocturnal asthma symptoms despite receiving at least moderate-dose inhaled corticosteroid and long-acting bronchodilators underwent a home sleep study using 'Embletta' portable diagnostic system. Patients with significant OSAS (apnoeahypopnoea index (AHI) ≥10/h) were randomized to receive either CPAP or conservative treatment for 3 months. Results: Among 145 patients recruited, 122 underwent sleep study with 41 (33.6%) having AHI ≥10/h. Patients with significant OSAS had higher BMI (27.4 (5.1) vs 25.1 (4.5) kg/m 2 , P = 0.016), bigger neck circumference (36.6 (3.1) vs 34.8 (3.6) cm, P = 0.006) and lower minimum SaO 2 (80.7 (6.6) vs 87.2 (3.9) %, P < 0.001). Using intention-to-treat analysis among 37 patients with AHI ≥10/h (CPAP group (n = 17) vs control group (n = 20)), there was no significant difference in Asthma Control Test score (CPAP 3.2 (2.7) vs control 2.4 (5.7), P = 0.568) but the CPAP group had a greater improvement in Epworth Sleepiness Scale (−3.0 (4.5) vs 0.5(3.8), P = 0.014), Asthma Quality of Life Questionnaire (0.6 (0.8) vs 0.02 (0.7), P = 0.022) and vitality domain in the SF-36 questionnaire (14.7 (16.8) vs 0.3 (16.2), P = 0.012) after 3 months. Data are presented as mean (SD) unless otherwise stated. Conclusion: A high prevalence of OSAS was found among patients with asthma and snoring. CPAP therapy for 3 months did not enhance asthma control but improved daytime sleepiness, quality of life and vitality. Clinical trial registration: NCT01383564 at ClinicalTrials.gov
INTRODUCTION
Obstructive sleep apnoea (OSA) syndrome (OSAS) and asthma are both common disorders, with prevalence of at least 4% among middle-aged males in a Hong Kong (HK) Chinese population 1 and 7.2% in young adults, 2 respectively. OSAS is characterized by repetitive episodes of upper airway obstruction, causing intermittent hypoxia, sleep fragmentation, impaired cognitive function and poor health status. 3 Asthma is a chronic inflammatory disorder of the airways leading to hyperresponsiveness with more symptoms at night. High prevalence of OSAS symptoms and moderate-to-severe OSAS has been reported in the asthmatic populations. [4] [5] [6] [7] Previous nonrandomized studies showed that continuous positive airway pressure (CPAP) treatment conferred a positive impact on asthma outcomes in patients with concomitant OSAS. [8] [9] [10] [11] In this study, we aimed to assess asthma
SUMMARY AT A GLANCE
In this randomized controlled trial involving patients with nocturnal asthma and snoring despite taking moderate-to-high-dose inhaled corticosteroid and long-acting bronchodilators, continuous positive airway pressure (CPAP) therapy for 3 months did not improve asthma control but led to better asthma-related quality of life and vitality than those on conservative treatment.
control, airway responsiveness, daytime sleepiness, cognitive function and health status at baseline and at 3 months after nasal CPAP treatment among asthma patients with nocturnal symptoms and OSAS.
METHODS
We conducted a prospective, randomized controlled trial (RCT) on 37 patients attending the Respiratory Clinic, Prince of Wales Hospital, with nocturnal asthma symptoms despite taking moderate-to-high-dose inhaled corticosteroids and long-acting bronchodilators during this study from 1 November 2012 to 12 January 2016. Inclusion criteria included: age ≥ 18 years and able to give consent; at least one nocturnal awakening or early morning awakening caused by asthmatic symptoms (cough, wheeze, chest tightness or breathlessness) in the past 2 weeks; habitual snoring; poor asthma control (defined by Asthma Control Test (ACT) score of 19 or below) despite having taken at least moderate dose of inhaled corticosteroid (Beclomethasone 500 μg or more per day equivalent) in the last 3 months. The components of ACT are included in Appendix S1 (Supplementary Information). We did not require demonstration of bronchial hyperreactivity in the diagnosis of asthma which was based on the American Thoracic Society (ATS) criteria.
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Exclusion criteria included: current smokers or those who quit smoking within the previous year or previous smoking history of >10 pack-years; cardiac failure; cerebrovascular disease; existing lung disease except asthma; dementia or poor hand function that would compromise the patients in undergoing a home sleep study or CPAP treatment, commercial driver or heavy machine operator. Recruited patients underwent a home sleep study with the Embletta device (Medcare, Reykjavik, Iceland), which has been validated against hospital-based polysomnography (PSG) in the HK Chinese population 13 and its operation is discussed in Appendix S1 (Supplementary Information). Patients were educated to complete an asthma-symptom diary (morning and evening) for 2 weeks before the sleep study with an assessment of peak expiratory flow variability and asthma symptoms.
Patients with apnoea-hypopnoea index (AHI) ≥ 10/h on sleep study were randomized to receive either CPAP or conservative treatment for 3 months in a balanced block design. Patients in the CPAP arm were given a CPAP education programme and titration which is described in Appendix S1 (Supplementary Information). All recruited patients completed the ACT questionnaire to assess asthma control, night-time symptoms score, subjective sleepiness with the Epworth Sleepiness Scale (ESS), Asthma Quality of Life Questionnaire (AQLQ), SF-36 quality of life questionnaire, Reflux Disease Questionnaire (RDQ) to assess gastro-oesophageal reflux (GER) symptoms, Score for Allergic Rhinitis (SFAR) questionnaire 14 for rhinitis symptoms control, spirometry and a bronchial challenge test for assessing bronchial reactivity. Researchers who administered the questionnaires were blinded to the intervention group, but not to the patients or the doctors who treated the asthma (details of the assessments can be found in Appendix S1 (Supplementary Information))1. All the assessments were conducted at baseline for all subjects and at 3 months after commencement of treatment in each group. Objective CPAP usage (h/day) was assessed at 1 and 3 months. The study was approved by the Joint Chinese University of Hong Kong -New Territories East Cluster Clinical Research Ethics Committee (CRE-2011.038T), and registered at ClinicalTrials.gov (Identifier: NCT01383564).
Study outcomes
The primary end point was the change in ACT score between the two groups after 3 months. Secondary end points were changes of nocturnal symptom score, AQLQ, ESS, SF-36, bronchial responsiveness, spirometry and peak expiratory flow rate (PEFR) variability at 3 months of the study for both treatment groups.
Sample size calculation
The sample size was calculated based on previous literature suggesting that around 40% of patients with uncontrolled asthma were suffering from OSAS. 10 As the minimally important difference of the ACT score was 3 points, 15 a sample size of 15 patients in each group achieved 80% power to detect an increase in ACT score of 3 as significant using a two-sided, unpaired t-test.
Statistical analysis
Data were analysed on an intention-to-treat (ITT) basis comparing the two groups in terms of demographics, ACT score, nocturnal symptoms score and ESS by including patients who had been randomized into the two treatment groups. Data are presented as mean and SD unless otherwise stated.
For comparisons between control and CPAP group at each time point, two-sided unpaired t-test and mixed linear model were used. Data analysis was performed with a commercially available statistical analysis software package (SPSS 22 for Windows, SPSS Inc., Chicago, IL, USA).
RESULTS
Altogether 145 subjects with nocturnal asthma, despite having received optimal medications during the period from 1 November 2012 to 12 January 2016, were recruited and randomized to CPAP group (n = 17) and control group (n = 20) as shown in Figure 1 . Among 122 patients who completed a home sleep study, 62 subjects (50.8%) had AHI ≥ 5/h while 23 subjects (18.9%) and 6 subjects (4.9%) had AHI ≥ 15and ≥ 30/h, respectively. Forty-one subjects (33.6%) with an AHI ≥ 10/h had their baseline characteristics compared with those with AHI < 10/h as shown in Table 1 . Patients with OSAS had higher BMI (27.4 vs 25.1 kg, P = 0.016), bigger neck circumference (36.6 vs 34.8 cm, P = 0.006) and lower minimum SaO 2 (80.7 vs 87.2%, P < 0.001). BMI and neck circumference were significantly correlated with AHI (r = 0.255, P = 0.008 and r = 0.247, P = 0.007, respectively). There was no significant correlation between age and ESS against AHI (Table 1) .
Among 37 patients with AHI ≥ 10/h who had undergone randomization, 17 were assigned to the CPAP group while 20 to the control group. There was significant difference in the morning PEFR but no difference in the PEFR variability or other parameters between two groups at baseline (Table 2) . There were two patients in the CPAP group who refused to use CPAP for the entire 3 months and declined to come back for assessment. Among the five patients who defaulted in the control group, one did not perform the bronchial challenge test at all time points while the rest did not come back for subsequent assessment. There was no significant difference in the baseline asthma control, degree of sleepiness or nocturnal symptoms among those defaulted assessment between the CPAP and control groups (baseline ACT score: 15.7 AE 2.1, ESS: 8.6 AE 6.8, nocturnal symptom score: 3.9 AE 0.4 and AHI: 17.8 AE 6.0/h). Among the CPAP group, the average CPAP pressure used was 14.7 AE 3.3 cm H 2 O with two patients (11.8%) requiring humidification. Most (94.1%) used nasal masks while only one patient used a full face mask for CPAP treatment. Two patients (11.8%) in CPAP group and 3 (15%) in control group could not perform bronchial challenge testing as their baseline forced expiratory volume in 1 s (FEV 1 ) was <60% predicted while 11 patients in the CPAP group and 10 in the control group had PD20 more than 6 mmol at baseline, 1 and 3 months after CPAP therapy. Although there was no significant difference in comparing the change of the ACT score (CPAP group 3.2 (2.7) vs control group 2.4 (5.7), P = 0.568), more patients achieved ACT score > 20 (CPAP group 57 vs 40%) among those who completed the study (Fig. 2) . Moreover, patients in the CPAP group had a greater improvement in AQLQ score (mean change 0.6 vs 0.02 in control, P = 0.022) and ESS (mean change −3.0 vs 0.5 in control, P = 0.014) ( Table 3) . Among all the categories of SF-36 questionnaires, there was significant improvement in vitality, with mean change of 14.7 in the CPAP group versus 0.3 in the control group (P = 0.012). There was no significant change in exacerbation rate, spirometry, PD20, SFAR and RDQ score between two groups at the end of the study.
Patients randomized into CPAP group used CPAP 5.0 (2.1) h/day at 1 month and 5.2 (1.8) h/day at 3 months, with 70.5% of subjects using CPAP for more than 4 h/ day. Twelve patients (70.6%) used CPAP for more than 4 h per night. There was no correlation between compliance and baseline ESS, AHI or nocturnal symptom score.
DISCUSSION
To our knowledge, this is the first RCT examining the impact of CPAP on asthma control in patients with habitual snoring and uncontrolled nocturnal asthma despite treatment with moderate-or high-dose inhaled steroid plus long-acting bronchodilators. A high prevalence of OSAS in this study confirmed the findings of a recent meta-analysis showing that the prevalence of OSA was 50% in adult asthma patients. 16 Coexisting asthma and OSA were shown to be associated with poorer sleep quality and more profound nocturnal hypoxaemia than either of the conditions. 17 Patients with asthma have an increased risk of new onset of OSA, 16, 18 suggesting that the alteration in pharyngeal airway patency, 19 systemic inflammation, 20 asthma medications 21 or sleep fragmentation due to asthma 22 may play a role in the development of OSAS although the underlying mechanistic links remain to be tested. 18 Moreover, co-morbid GER disease related to transient Asthma control after CPAP therapy lower oesophageal sphincter relaxation 23 causing pharyngeal spasm and mucosal inflammation 24 may contribute to pathogenesis although our patients did not have significant GER symptoms, reflected by the RDQ score lower than 3 as the cut-off point. 25 Although rhinitis and nasal obstruction contribute to sleepdisordered breathing, 8 there was no significant difference in the SFAR score between OSAS and non-OSAS patients. Interestingly, not only could asthma and the associated co-morbidities contribute to the development of OSAS, OSAS symptoms were also significantly associated with neutrophilic airway inflammation in asthma and poor asthma control with increased asthma symptoms, beta-agonist use, healthcare utilization and worse asthma quality of life. [26] [27] [28] The possible bidirectional relationship between the two diseases was further demonstrated in a recent retrospective study which found that asthmatic patients with OSA had a substantially greater decline in FEV 1 (72.4 AE mL/year in severe OSA) in 5-year follow-up than those without OSA (24.3 AE 27.5 mL/year) in a severity-dependent manner. 29 Achieving and maintaining symptom control is a primary goal of asthma management. Although there was significant change of ACT score after 3 months of CPAP therapy in our study, it was not statistically significant Data are mean AE SD. † P < 0.05 compared with subjects with AHI ≥ 10/h. ‡ 21 Subjects in all participants had PD20 < 6 μmol/L for analysis. § Eight subjects in the CPAP group had PD20 < 6 μmol/L for analysis. ¶ 13 Subjects in the control group had PD20 < 6 μmol/L for analysis. ACT, Asthma Control Test; AHI, apnoea-hypopnoea index; AQLQ, Asthma Quality of Life Questionnaire; BCT, bronchial challenge test; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Scale; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastro-oesophageal reflux disease; LABA, long-acting beta 2 agonist; PD20, Provocation dose causing a 20% decline in FEV1; PEFR, peak expiratory flow rate; RDQ, Reflux Disease Questionnaire; SaO 2 , oxygen saturation; SFAR, Score for Allergic Rhinitis.
when compared with the control group. While a previous history of symptom control stability is the best indicator of future stability, 30 patients with suboptimal asthma control as in our study are very likely to have variation of asthma control over time. The ACT was originally designed as a short, simple and patient-based tool to identify uncontrolled asthma 31 and was a useful tool to facilitate the physicians monitoring of the progress with treatment. 32 However, this simple 5-item questionnaire may not be sensitive enough to detect patients who might have underestimated their asthma control (e.g. poor perceivers of symptoms) when filling in the ACT questionnaire. A previous study has shown that nearly one-fourth of asthma subjects with ACT >20 had escalation of asthma treatment by the physicians. 33 Therefore, although ACT is a simple tool in the busy clinic setting, further history taking by the physicians or use of more detailed questionnaires would be necessary to assess the patient's response to treatment. A previous study showed that long-term CPAP treatment improved asthma control, with improvement of ACT from 15.4 to 19.8 34 but the reliability of the patients' responses was questionable as patients needed to recall their CPAP usage from many years earlier. Nevertheless, the current RCT has shown that CPAP treatment for 3 months improved daytime sleepiness, quality of life and the domains of vitality in the SF-36 questionnaires, as also shown by a previous prospective observational study.
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The beneficial effect of CPAP on objective asthma control as measured by methacholine challenge is not clear because 37% of our patients recruited had a negative result on the bronchial challenge test, as reflected by the lack of FEV 1 fall >20% after inhalation of 6 μmol of methacholine while 21% (26 subjects) could not perform the test as their baseline FEV 1 was <60%. Only 0.415 † Three subjects in the CPAP group and five in the control group had the PD20 < 6 μmol for analysis. ACT, Asthma Control Test; AHI, apnoea-hypopnoea index; AQLQ, Asthma Quality of Life Questionnaire; BCT, bronchial challenge test; CPAP, continuous positive airway pressure; ESS, Epworth Sleepiness Scale; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; GERD, gastro-oesophageal reflux disease; LABA, long-acting beta 2 agonist; PD20, Provocation dose causing a 20% decline in FEV1; PEFR, peak expiratory flow rate; RDQ, Reflux Disease Questionnaire; SaO 2 , oxygen saturation; SFAR, Score for Allergic Rhinitis.
17% had a positive bronchial challenge test valid for analysis at baseline. While 30% of patients with a negative methacholine challenge test experienced asthma symptoms requiring medical intervention after withdrawing all medications, 35 a negative bronchial challenge does not rule out asthma especially those with seasonal asthma, 36 occupational asthma 37 and patients taking intensive anti-inflammatory medication. 38 Chronic mechanical strain produced by CPAP was shown to reduce airway responsiveness in an animal study 39 and 1-week CPAP therapy in human subjects. 40 However, poor CPAP adherence and no significant change in the bronchial reactivity were shown in another RCT after 12 weeks of CPAP among patients with asthma. 41 Whether better adherence of CPAP therapy would lead to change in bronchial reactivity remains to be tested in larger RCT.
Our study has several limitations. First, the diagnosis of OSAS was based on a portable home sleep study, which recorded the number of apnoeas/hypopnoeas per hour of recording instead of per hour of sleep. The gold standard for diagnosing OSAS is in-laboratory PSG which is expensive and technically demanding. The American Academy of Sleep Medicine (AASM) guidelines recommend that a routine use of portable sleeprecording devices may be accepted for diagnosing OSAS in conjunction with comprehensive sleep evaluation. 42 Second, the clinical course of asthma patients might fluctuate depending on inter-current infections, exposure to allergens, weather changes, etc. Three months of follow-up might not be long enough to see the persistent benefit of asthma control. Third, as habitual snoring was one of the inclusion criteria, the prevalence of OSA could not be overgeneralized to all patients with nocturnal asthma. Fourth, the lack of evaluation of pollution and biomarkers might have hindered a better understanding of the population and asthma control. In addition, there could be potential influence on the subjective outcome as the patients involved were not blinded. However, asthma patients on sham CPAP had poor CPAP adherence in a previous study (52% using CPAP ≤4 h/night) and suffered from more nasal congestion and headache. 43 Moreover, the relatively small sample size was not powered to detect changes in spirometry or bronchial challenge studies. Further investigation of a wider battery of tests with a longer follow-up is warranted.
In conclusion, a high prevalence of OSAS was found among patients with nocturnal asthma and snoring despite treatment with moderate-to-high-dose inhaled corticosteroids and long-acting bronchodilators. Use of nocturnal CPAP for 3 months did not enhance asthma control but improved asthma-related quality of life, daytime sleepiness and vitality.
